Fauna Bio lands new investment to advance pulmonary fibrosis program

Squirrel

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Silicon Valley longevity biotech Fauna Bio has secured new investment from LifeSpan Vision Ventures, a venture capital firm that invests in companies developing therapeutics focusing on longevity and aging reversal. The new funding will be used to advance the company’s lead program in pulmonary fibrosis.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LT Staff

Longevity.Technology's in-house writing staff.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Old dogs, new funding: Dog Aging Project fetches $29m from NIH

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE